Skip to main content
SpringerLink
Log in

ÖGR-Jahrestagung 2018

Systemische Sklerose – ein Update

  • aktuell
  • Published:
rheuma plus Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940–944

    Article  Google Scholar 

  2. Moore OA, Goh N, Corte T et al (2013) Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis interstitial lung disease. Baillieres Clin Rheumatol 52(1):155–160

    Google Scholar 

  3. Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their realtionship to outcome. Am J Respir Crit Care Med 165(12):1581–1586

    Article  Google Scholar 

  4. Nannini C, West CP, Erwin PJ et al (2008) Effects of cyclophoshamide on pulmonary funtion in patients with scleroderma and interstitial ling disease: a systematic review and meta-analysis of randomized controlled trieals and observational prospective cohort studies. Arthritis Res Ther 10(5):R124

    Article  Google Scholar 

  5. Tashkin DP, Roth MD, Clements PJ et al (2016) Mydophenolat mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719

    Article  CAS  Google Scholar 

  6. Jordan S, Distler JH, Maurer B et al (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74(6):1188–1194

    Article  CAS  Google Scholar 

  7. Burt RK, Shah SJ, Dill K et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with plus cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet 378(9790):498–506

    Article  CAS  Google Scholar 

  8. Van Laar JM, Farge D, Sont JK et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in duffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498

    Article  Google Scholar 

  9. Sullivan KM, Goldmuntz EA, Keyes-Elstein L et al (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 378(1):35–47

    Article  Google Scholar 

  10. Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR Recommendations for the Treatment of Systemic Sclerosis. Ann Rheum Dis 76(8):1327–1339

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Systemische Sklerose – ein Update. rheuma plus 18, 54–57 (2019). https://doi.org/10.1007/s12688-019-0234-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12688-019-0234-2

Search

Navigation